France: Ipsen expands oncology assets through acquisition of Epizyme

Euronext Paris listed Ipsen, a global, mid-sized biopharmaceutical company focused on oncology, rare disease and neuroscience, is acquiring Nasdaq listed Epizyme, a US-based fully integrated, commercial-stage biopharmaceutical company. The transaction is anticipated to close by the end of the third quarter of 2022. Ipsen, through a subsidiary, will initiate a tender offer to acquire all…

You must be a HMI Subscriber to view this content.

Subscribe Now »